Medicaid prescription cost containment and schizophrenia: A retrospective examination

Medical Care

Volumn 48, Issue 5, 2010, Pages 440-447

  Farley, Joel F ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Antipsychotics; Cost containment; Medicaid; Pharmacy benefits; Prescription drugs; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; COST CONTROL; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COST CONTROL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICAID; MEDICATION ADHERENCE; MENTAL HEALTH SERVICES; MISSISSIPPI; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 77951622040     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181d502bd     Document Type: Article

References (28)

1. Smith V, Gifford K, Ellis E, et al. Headed for a crunch: an update on Medicaid spending, coverage and policy heading into an economic downturn. Available at: http://www.kff.org/medicaid/upload/7815.pdf. Accessed July 9, 2009.
2. Crowley J, Ashner R, Elam L. Kaiser Commission on Medicaid and the Uninsured. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update. Available at: http://www.kff.org/medicaid/upload/ State-Medicaid-Outpatient-Prescription-Drug-Policies-Findings-from-a-National- Survey-2005-Update-report.pdf. Accessed July 10, 2009.
3. Lewis-Payton R. Mississippi Division of Medicaid Fiscal Year 2002 Annual Report. Available at: http://www.medicaid.ms.gov/AnnualReports/2002.pdf. Accessed July 9, 2009.
4. House Bill 1200 (cost containment). Moody, trans. A 043-0013-0117. Regular ed (2002).
5. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
6. Huskamp HA. Managing psychotropic drug costs: will formularies work? Health Aff (Millwood). 2003;22:84-96.
7. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
8. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
9. Zeber JE, Grazier KL, Valenstein M, et al. Effect of a medication copayment increase in veterans with schizophrenia. Am J Manag Care. 2007;13(6 pt 2):335-346.
10. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
11. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30:255-264.
12. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
13. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.
14. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34:173-180.
15. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23:2305-2312.
16. Indiana State House Bill No. 1233, 2nd Regular Session, 112th General Assembly. 112 ed (2002).
17. Minnesota State Legislature, Chapter 375. S.F. No.3099, 3rd Engrossment, 82nd Legislative Sess. 82 ed (2002).
18. Persinger G. Pharmaceutical Benefits Under State Medical Assistance Programs. Reston, VA: National Pharmaceutical Council; 2003.
19. Kaiser Family Foundation. Medicaid Benefits Online Database: Prescription Drugs. Available at: http://medicaidbenefits.kff.org. Accessed November 13, 2009.
20. Lurie N, Popkin M, Dysken M, et al. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry. 1992; 43:69-71.
21. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
22. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12:989-995.
23. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict health expenditures. Am J Manag Care. 2006; 12:110-117.
24. Schneeweiss R, Cherkin DC, Hart LG, et al. Diagnosis clusters adapted for ICD-9-CM and ICHPPC-2. J Fam Pract. 1986;22:69-72.
25. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
26. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494.
27. Berndt ER. Pharmaceuticals in US health care: determinants of quantity and price. J Econ Perspect. 2002;16:45-66.
28. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsy-chotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.